Lung Cancer Journal Articles and Videos
Is Gastrointestinal Metastasis of Primary Lung Malignancy as Rare as Reported in the Literature? A Comparison Between...
Oncology & Hematology Review, 2016;12(1):51–7 DOI: http://doi.org/10.17925/OHR.2016.12.01.51
Current and Future Therapeutics for Patients with Non-small Cell Lung Cancer and Known Activating Mutations in...
Oncology & Hematology Review, 2015;11(2):128–34 DOI: http://doi.org/10.17925/OHR.2015.11.02.128
Rociletinib—An Investigational Therapy in Patients with Previously Treated EGFR Mutant-positive Non-small Cell Lung...
Oncology & Hematology Review, 2015;11(2):122–7 DOI: http://doi.org/10.17925/OHR.2015.11.02.122
Managing Immunotherapy-related Side Effects
Oncology & Hematology Review, 2015;11(2):143–4 DOI: http://doi.org/10.17925/OHR.2015.11.02.143
Head of Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center in Lyon.
Maurice Pérol, M.D., was Associate Professor of Pneumology and Head of the Department of Thoracic Oncology at the Croix-Rousse University Hospital in Lyon, France from 1993 until 2011. He joined in 2011 the Medical Oncology Department of Léon Bérard Cancer Center in Lyon, in which he is responsible for Thoracic Oncology.
His fields of scientific work include clinical phase I, II and III studies in lung cancer, especially in advanced non-small cell lung cancer; this work involves being a principal investigator or key investigator in several French or international cooperative studies. Of note, he was the principal investigator of the IFCT-GFPC 0502 maintenance French study which involves more than 70 centers in France and the co-principal investigator of the international REVEL phase III study assessing ramucirumab in second-line treatment of NSCLC.
He is an active member of many scientific societies, including ASCO, IASLC and ESMO, and collaborative groups. He was the Chairman of the Groupe Français de Pneumo-Cancérologie (GFPC) from 1998 to 2002 and Executive Board member of the French Cooperative Group of Thoracic Oncology "Intergroupe Francophone de Cancérologie Thoracique" (IFCT) from 1999 to 2003; he is member of the IFCT Scientific Board since 2003. He is the author or co-author of more than 140 publications in peer-reviewed journals.